RETATRUTIDE
GLP-1/GIP/GCGR AGONIST 10MG
Description:
Retatrutide 10 mg is an advanced investigational peptide that targets GLP-1, GIP, and glucagon (GCGR) receptors. This triple-agonist approach is being studied for its potential to support weight management, appetite control, improved metabolic function, and blood sugar regulation. Designed for research purposes, it represents a next-generation approach to metabolic health.
Note: These are potential or investigated effects from clinical and experimental data and are not approved medical claims; Retatrutide is an investigational peptide and not an authorized treatment in most countries.
Activates triple receptor pathways (GLP-1, GIP, and GCGR), driving multi-mechanism metabolic stimulation, enhanced energy expenditure, and fat oxidation.
Supports weight management and appetite control, helping promote satiety, reduce caloric intake, and accelerate body fat loss in research models.
Promotes improved metabolic function and blood sugar regulation, assisting in glycemic control, lipid metabolism, and metabolic efficiency.
- There is no universally accepted, regulatory-approved dosing schedule for Retatrutide; any use should follow local laws and, ideally, specialist guidance in a formal research or clinical context.
- Puretech Retatrutide provides 10 mg per vial as a lyophilized powder for subcutaneous (SC) injection; published experimental protocols typically utilize a once-weekly step-up titration schedule (often starting at 2 mg and gradually increasing) after reconstitution with bacteriostatic water, but exact dosage, titration, and cycle length must be determined by qualified professionals.
- Reconstituted solutions should be stored under refrigeration, handled using sterile protocols, and administered consistently while closely monitoring tolerance and metabolic markers.
- Retatrutide is an investigational agent and is not approved for over-the-counter human consumption; long-term human safety data are still being evaluated, and medical bodies caution against unsupervised use.
- Reported and theoretical risks include gastrointestinal symptoms (such as nausea, diarrhea, vomiting, and constipation), mild skin sensitivity or dysesthesia, transient heart rate elevations, and potential gallbladder or pancreatic considerations.
- As with other investigational peptides, there is potential for unknown adverse effects, contamination, and strict prohibitions under athletic anti-doping rules; the product should be kept out of reach of children and handled only where legally permitted under expert oversight.
- Sourced from premium APIs and manufactured in GMP facilities, Puretech Retatrutide passes independent HPLC and MS testing for 99%+ purity and accurate sequence verification. Free from fillers, heavy metals, or contaminants—backed by batch-specific certificates of analysis. Lyophilized and sealed under an inert atmosphere to preserve bioactivity for peak performance.